Magali Pettazzoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Magali Pettazzoni has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Roseline Froissart
Department of Biochemistry and Molecular Biology, Inborn Error of Metabolism Unit Hospices Civils de Lyon Lyon France
6 shared publicationsNathalie Guffon
National Reference Centre for Hereditary Metabolic Diseases, Hospices Civils de Lyon, 69500 Bron, France
4 shared publicationsAlain Fouilhoux
National Reference Centre for Hereditary Metabolic Diseases, Hospices Civils de Lyon, 69500 Bron, France
3 shared publicationsAnaïs Brassier
Department of Pediatric Metabolism, Reference Center of Inherited Metabolic Disorders, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, 75015 Paris, France
3 shared publicationsCécile Pagan
Department of Biochemistry and Molecular Biology, Inborn Errors of Metabolism Unit, Hospices Civils de Lyon, 69500 Bron, France
3 shared publications- Roseline Froissart
Laboratory of Biochemistry and Molecular Biology UM Inherited Metabolic and Red Blood Cell Diseases Hospices Civils de Lyon, Hospital Cluster East, Bron Cedex, France
3 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (5) , e70117
Unmasking Mucopolysaccharidosis Type I in a Patient With Wolf–Hirschhorn Syndrome: Diagnostic Overshadowing
Mucopolysaccharidosis Type I (MPS I) is a rare lysosomal storage disorder caused by α‐ l ‐iduronidase deficiency, leading to glycosaminoglycan accumulation and multisystem involvement. Wolf–Hirschhorn Syndrome (WHS) is a chromosomal disorder characterized by growth delay, dysmorphism, and developmental impairment. Because the IDUA gene is located within the 4p16.3 region, the coexistence of WHS and MPS I is biologically plausible but rarely documented. We describe a 2‐year‐old child of North African origin presenting with dysmorphic features, developmental delay, and thoracolumbar kyphosis. Chromosomal microarray analysis identified a 5.8 Mb deletion at 4p16.3–p16.2, confirming WHS at 17 months. However, additional clinical features remained unexplained. Incidentally, during a routine blood test, a blood smear revealed lymphocytes with metachromatic inclusions, raising suspicion of a lysosomal storage disorder. An enzymatic assay confirmed α‐ l ‐iduronidase deficiency, and molecular analysis identified biallelic pathogenic alterations in the IDUA gene located on chromosome 4p16.3, establishing the diagnosis of MPS I at 18 months. Enzyme replacement therapy was initiated at 19 months and was associated with stabilization of the somatic manifestations of MPS I, including improvement in respiratory symptoms. This observation highlights the risk of diagnostic overshadowing in rare diseases. A confirmed genetic diagnosis should not preclude further investigations when clinical features are discordant.
- 6 September 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (5) , e70117
Open AccessUnmasking Mucopolysaccharidosis Type I in a Patient With Wolf–Hirschhorn Syndrome: Diagnostic Overshadowing
Mucopolysaccharidosis Type I (MPS I) is a rare lysosomal storage disorder caused by α‐ l ‐iduronidase deficiency, leading to glycosaminoglycan accumulation and multisystem involvement. Wolf–Hirschhorn Syndrome (WHS) is a chromosomal disorder characterized by growth delay, dysmorphism, and developmental impairment. Because the IDUA gene is located within the 4p16.3 region, the coexistence of WHS and MPS I is biologically plausible but rarely documented. We describe a 2‐year‐old child of North African origin presenting with dysmorphic features, developmental delay, and thoracolumbar kyphosis. Chromosomal microarray analysis identified a 5.8 Mb deletion at 4p16.3–p16.2, confirming WHS at 17 months. However, additional clinical features remained unexplained. Incidentally, during a routine blood test, a blood smear revealed lymphocytes with metachromatic inclusions, raising suspicion of a lysosomal storage disorder. An enzymatic assay confirmed α‐ l ‐iduronidase deficiency, and molecular analysis identified biallelic pathogenic alterations in the IDUA gene located on chromosome 4p16.3, establishing the diagnosis of MPS I at 18 months. Enzyme replacement therapy was initiated at 19 months and was associated with stabilization of the somatic manifestations of MPS I, including improvement in respiratory symptoms. This observation highlights the risk of diagnostic overshadowing in rare diseases. A confirmed genetic diagnosis should not preclude further investigations when clinical features are discordant.
- Open Access
- 19 August 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 149 (1-2) , 110238
Multiplex MSMS measurement of lysosomal enzymes enables incidental diagnosis of acid sphingomyelinase deficiency in patients evaluated for Gaucher disease
- 19 August 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 149 (1-2) , 110238
Open AccessMultiplex MSMS measurement of lysosomal enzymes enables incidental diagnosis of acid sphingomyelinase deficiency in patients evaluated for Gaucher disease
- Open Access
- 23 April 2026
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 54 (10) , 501-508
Profils des marqueurs sériques maternels de la trisomie 21 : révision des commentaires et des conduites à tenir
- 23 April 2026
- Published by Elsevier in Gynécologie Obstétrique Fertilité & Sénologie
- Vol. 54 (10) , 501-508
Open AccessProfils des marqueurs sériques maternels de la trisomie 21 : révision des commentaires et des conduites à tenir
- Open Access
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Multiplex MSMS measurement of lysosomal enzymes enables incidental diagnosis of acid sphingomyelinase deficiency in patients evaluated for Gaucher disease
BackgroundAcid sphingomyelinase deficiency (ASMD) is a rare lysosomal storage disorder caused by pathogenic variants in the SMPD1 gene, resulting in deficient acid sphingomyelinase activity and progressive lipid accumulation in multiple organs. Owing to its clinical heterogeneity and lower prevalence compared with Gaucher disease (GD), ASMD remains underrecognized, particularly given the substantial overlap in clinical features such as hepatosplenomegaly and cytopenias. We evaluated the contribution of multiplex measurement of enzyme activities by tandem mass spectrometry (MS/MS) on dried blood spots (DBS) for the incidental detection of ASMD in patients referred for suspected GD.MethodsAll DBS samples referred to our center between 2018 and 2025 underwent multiplex MS/MS analysis, measuring six lysosomal enzyme activities, including acid sphingomyelinase and glucocerebrosidase. Enzymatic deficiencies were confirmed by molecular analysis of SMPD1 or GBA and by plasma biomarker assessment.ResultsAmong 37,277 DBS samples analyzed, 5,765 were referred for suspected GD and/or ASMD. ASMD was confirmed in 56 patients and GD in 56 patients. Notably, 8 ASMD cases (14.3%) were incidentally detected among patients initially suspected of having GD, highlighting the diagnostic yield of parallel lysosomal enzyme testing. Three of these patients subsequently initiated enzyme replacement therapy.ConclusionMultiplex MS/MS analysis on DBS enables systematic and simultaneous evaluation of GD and ASMD in routine practice. This strategy improves differential diagnosis, reduces diagnostic delay, and facilitates timely therapeutic decision-making, ultimately enhancing patient management.
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultiplex MSMS measurement of lysosomal enzymes enables incidental diagnosis of acid sphingomyelinase deficiency in patients evaluated for Gaucher disease
BackgroundAcid sphingomyelinase deficiency (ASMD) is a rare lysosomal storage disorder caused by pathogenic variants in the SMPD1 gene, resulting in deficient acid sphingomyelinase activity and progressive lipid accumulation in multiple organs. Owing to its clinical heterogeneity and lower prevalence compared with Gaucher disease (GD), ASMD remains underrecognized, particularly given the substantial overlap in clinical features such as hepatosplenomegaly and cytopenias. We evaluated the contribution of multiplex measurement of enzyme activities by tandem mass spectrometry (MS/MS) on dried blood spots (DBS) for the incidental detection of ASMD in patients referred for suspected GD.MethodsAll DBS samples referred to our center between 2018 and 2025 underwent multiplex MS/MS analysis, measuring six lysosomal enzyme activities, including acid sphingomyelinase and glucocerebrosidase. Enzymatic deficiencies were confirmed by molecular analysis of SMPD1 or GBA and by plasma biomarker assessment.ResultsAmong 37,277 DBS samples analyzed, 5,765 were referred for suspected GD and/or ASMD. ASMD was confirmed in 56 patients and GD in 56 patients. Notably, 8 ASMD cases (14.3%) were incidentally detected among patients initially suspected of having GD, highlighting the diagnostic yield of parallel lysosomal enzyme testing. Three of these patients subsequently initiated enzyme replacement therapy.ConclusionMultiplex MS/MS analysis on DBS enables systematic and simultaneous evaluation of GD and ASMD in routine practice. This strategy improves differential diagnosis, reduces diagnostic delay, and facilitates timely therapeutic decision-making, ultimately enhancing patient management.
- 27 February 2026
- Published by Elsevier in Archives de Pédiatrie
- Vol. 33 (3) , 105483
Metachromatic leukodystrophy (MLD) in France: the views of family caregivers on the diagnosis of the disease, its daily burden on their child, and the whole family
- 27 February 2026
- Published by Elsevier in Archives de Pédiatrie
- Vol. 33 (3) , 105483
Metachromatic leukodystrophy (MLD) in France: the views of family caregivers on the diagnosis of the disease, its daily burden on their child, and the whole family
- Open Access
- 18 February 2026
- Published by Elsevier in SSRN Electronic Journal
Plasma KL-6 Reflects Pulmonary Severity and Longitudinal Response to Enzyme Replacement Therapy in Acid Sphingomyelinase Deficiency Type B
Acid sphingomyelinase deficiency (ASMD) type B is frequently complicated by interstitial lung disease without validated circulating pulmonary biomarkers. In this retrospective longitudinal study of five patients treated with enzyme replacement therapy, plasma KL-6 was evaluated in relation to CT-based severity, DLCO, and treatment response. KL-6 correlated with baseline pulmonary involvement and decreased under therapy. A transient rise occurred during SARS-CoV-2 infection. KL-6 may reflect dynamic alveolar epithelial injury in ASMD.
- 18 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPlasma KL-6 Reflects Pulmonary Severity and Longitudinal Response to Enzyme Replacement Therapy in Acid Sphingomyelinase Deficiency Type B
Acid sphingomyelinase deficiency (ASMD) type B is frequently complicated by interstitial lung disease without validated circulating pulmonary biomarkers. In this retrospective longitudinal study of five patients treated with enzyme replacement therapy, plasma KL-6 was evaluated in relation to CT-based severity, DLCO, and treatment response. KL-6 correlated with baseline pulmonary involvement and decreased under therapy. A transient rise occurred during SARS-CoV-2 infection. KL-6 may reflect dynamic alveolar epithelial injury in ASMD.
- Open Access
- 27 October 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-25
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher disease
Gaucher disease (GD) is a rare autosomal recessive lysosomal disorder caused by glucocerebrosidase deficiency, with a prevalence in France of around 1/130,000 people. The clinical picture of GD is very heterogeneous, ranging from lifelong asymptomatic forms to severe forms with onset during childhood, such as GD type 2 (< 1% of cases). GD type 1, the most common form (95% of cases), manifests with varying degrees of organomegaly, cytopenia and bone manifestations. Progressive encephalopathy of varying severity is also observed in GD type 3. Symptoms may result in acute and/or chronic pain and asthenia, and lead to disability. The aim of the French National Diagnosis and Care Protocol (Protocole National de Diagnostic et de Soins; PNDS) is to provide health care professionals with guidance for the optimal management and care of patients with GD. GD diagnosis is usually based on laboratory analyses revealing low or absent glucocerebrosidase activity, and can be confirmed by identification of glucocerebrosidase ( GBA1 ) gene pathogenic variants. Additional assessments should include biological analyses (hemogram test, serum protein electrophoresis, and measurement of GD biomarkers), imaging examinations (X-rays, abdominal and bone magnetic resonance imaging, bone densitometry, echocardiography), and electrocardiogram. Patient management in France is multidisciplinary and should be coordinated by a GD specialist, in conjunction with the Committee for the Evaluation and Treatment of Gaucher Disease, the Reference Center for Lysosomal Diseases or a reference/competence center for inherited metabolic diseases. The indication for treatment is not systematic and is based on the presence of clinical, biological, and imaging criteria. Current treatments such as intravenous enzyme replacement therapy or oral substrate reduction therapy, generally lead to significant improvements in disease characteristics within one to five years and early initiation can prevent complications. Follow-up should include a clinical examination, biological analyses to monitor disease biomarkers twice a year then yearly for stable patients, and imaging evaluations initially every year and then every 3 to 4 years for patients with stable disease in whom therapeutic objectives have been achieved. Intercurrent pathologies can be managed by the attending physician in collaboration with a GD specialist.
- 27 October 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-25
Open AccessFrench national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher disease
Gaucher disease (GD) is a rare autosomal recessive lysosomal disorder caused by glucocerebrosidase deficiency, with a prevalence in France of around 1/130,000 people. The clinical picture of GD is very heterogeneous, ranging from lifelong asymptomatic forms to severe forms with onset during childhood, such as GD type 2 (< 1% of cases). GD type 1, the most common form (95% of cases), manifests with varying degrees of organomegaly, cytopenia and bone manifestations. Progressive encephalopathy of varying severity is also observed in GD type 3. Symptoms may result in acute and/or chronic pain and asthenia, and lead to disability. The aim of the French National Diagnosis and Care Protocol (Protocole National de Diagnostic et de Soins; PNDS) is to provide health care professionals with guidance for the optimal management and care of patients with GD. GD diagnosis is usually based on laboratory analyses revealing low or absent glucocerebrosidase activity, and can be confirmed by identification of glucocerebrosidase ( GBA1 ) gene pathogenic variants. Additional assessments should include biological analyses (hemogram test, serum protein electrophoresis, and measurement of GD biomarkers), imaging examinations (X-rays, abdominal and bone magnetic resonance imaging, bone densitometry, echocardiography), and electrocardiogram. Patient management in France is multidisciplinary and should be coordinated by a GD specialist, in conjunction with the Committee for the Evaluation and Treatment of Gaucher Disease, the Reference Center for Lysosomal Diseases or a reference/competence center for inherited metabolic diseases. The indication for treatment is not systematic and is based on the presence of clinical, biological, and imaging criteria. Current treatments such as intravenous enzyme replacement therapy or oral substrate reduction therapy, generally lead to significant improvements in disease characteristics within one to five years and early initiation can prevent complications. Follow-up should include a clinical examination, biological analyses to monitor disease biomarkers twice a year then yearly for stable patients, and imaging evaluations initially every year and then every 3 to 4 years for patients with stable disease in whom therapeutic objectives have been achieved. Intercurrent pathologies can be managed by the attending physician in collaboration with a GD specialist.
- 11 March 2025
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 145 (1) , 109081
Acid sphingomyelinase deficiency: Laboratory diagnosis, genetic and epidemiologic aspects of a 50-year French cohort
- 11 March 2025
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 145 (1) , 109081
Acid sphingomyelinase deficiency: Laboratory diagnosis, genetic and epidemiologic aspects of a 50-year French cohort
- Open Access
- 7 May 2024
- Published by Elsevier in Journal of Lipid Research
- Vol. 65 (6) , 100557
Intestinal absorption of sphingosine: new insights on generated ceramide species using stable isotope tracing in vitro
- 7 May 2024
- Published by Elsevier in Journal of Lipid Research
- Vol. 65 (6) , 100557
Open AccessIntestinal absorption of sphingosine: new insights on generated ceramide species using stable isotope tracing in vitro
- Top Cited PapersOpen Access
- 17 April 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-28
Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann–Pick disease types A, B and A/B)
Background: Acid Sphingomyelinase Deficiency (ASMD) is a rare autosomal recessive disorder caused by mutations in the SMPD1 gene. This rarity contributes to misdiagnosis, delayed diagnosis and barriers to good care. There are no published national or international consensus guidelines for the diagnosis and management of patients with ASMD. For these reasons, we have developed clinical guidelines that defines standard of care for ASMD patients. Methods: The information contained in these guidelines was obtained through a systematic literature review and the experiences of the authors in their care of patients with ASMD. We adopted the Appraisal of Guidelines for Research and Evaluation (AGREE II) system as method of choice for the guideline development process. Results: The clinical spectrum of ASMD, although a continuum, varies substantially with subtypes ranging from a fatal infantile neurovisceral disorder to an adult-onset chronic visceral disease. We produced 39 conclusive statements and scored them according to level of evidence, strengths of recommendations and expert opinions. In addition, these guidelines have identified knowledge gaps that must be filled by future research. Conclusion: These guidelines can inform care providers, care funders, patients and their carers about best clinical practice and leads to a step change in the quality of care for patients with ASMD with or without enzyme replacement therapy (ERT).
- 17 April 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-28
Top Cited PapersOpen AccessConsensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann–Pick disease types A, B and A/B)
Background: Acid Sphingomyelinase Deficiency (ASMD) is a rare autosomal recessive disorder caused by mutations in the SMPD1 gene. This rarity contributes to misdiagnosis, delayed diagnosis and barriers to good care. There are no published national or international consensus guidelines for the diagnosis and management of patients with ASMD. For these reasons, we have developed clinical guidelines that defines standard of care for ASMD patients. Methods: The information contained in these guidelines was obtained through a systematic literature review and the experiences of the authors in their care of patients with ASMD. We adopted the Appraisal of Guidelines for Research and Evaluation (AGREE II) system as method of choice for the guideline development process. Results: The clinical spectrum of ASMD, although a continuum, varies substantially with subtypes ranging from a fatal infantile neurovisceral disorder to an adult-onset chronic visceral disease. We produced 39 conclusive statements and scored them according to level of evidence, strengths of recommendations and expert opinions. In addition, these guidelines have identified knowledge gaps that must be filled by future research. Conclusion: These guidelines can inform care providers, care funders, patients and their carers about best clinical practice and leads to a step change in the quality of care for patients with ASMD with or without enzyme replacement therapy (ERT).